echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Br J Dermatol: Dupilumab is effective in improving symptoms and signs in patients with atopic dermatitis

    Br J Dermatol: Dupilumab is effective in improving symptoms and signs in patients with atopic dermatitis

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Dupilumab is an antibody against interleukin-4 receptor alpha used to treat atopic dermatitis (A.


    Patients with AD were enrolled in this randomized, double-blind, placebo-controlled, parallel-group Phase III study conducted from December 2018 to February 2020 to receive dubilumab (300 mg) or placebo every 2 weeks , for 16 weeks, and followed up for 12 wee.


    RESULTS: 165 patients (mean age 30-6 years; 71-5% male patients) were randomly assigned: 82 to receive dupilumab and 83 to receive place.


    Taken together, the results of this study suggest that in Chinese adult patients, dupilumab can effectively improve the symptoms and signs of AD with a favorable safety profi.


    Original source:

    Y Zhao, et .


    The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, controlled study

     

    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.